CK-0045

DRUG2 trials

Sponsors

Cytoki Pharma

Conditions

HealthyObesity and OverweightType 2 Diabetes Mellitus (T2DM)

Phase 1

A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy Participants and Otherwise Healthy Participants With Obesity

CompletedNCT05712876

Cytoki PharmaHealthy

Start: 2022-12-26End: 2024-01-04Updated: 2024-01-10

Phase 2

CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes

TerminatedNCT06611930

Cytoki PharmaObesity and Overweight, Type 2 Diabetes Mellitus (T2DM)

Start: 2024-09-06End: 2025-10-21Updated: 2026-02-20